Immune modulation by mesenchymal stem cells

Experimental Cell Research

Volumn 312, Issue 12, 2006, Pages 2169-2179

  Rasmusson, Ida ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Cytotoxicity; Graft versus host disease; Immune System; Multipotent stem cells; Proliferation; Prostaglandin; T cells

Indexed keywords

ALLOANTIGEN; CYCLOSPORIN A;

ACUTE GRAFT VERSUS HOST DISEASE; ACUTE GRANULOCYTIC LEUKEMIA; ADOPTIVE IMMUNOTHERAPY; ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION; ANTIGEN PRESENTING CELL; ANTIGEN RECOGNITION; BONE MARROW; CELL MEDIATED CYTOTOXICITY; CLINICAL TRIAL; CLONAL ANERGY; COMPREHENSION; GRAFT VERSUS HOST REACTION; HEMATOLOGIC MALIGNANCY; HOMEOSTASIS; HUMAN; IMMUNOMODULATION; IMMUNOREACTIVITY; IMMUNOSUPPRESSIVE TREATMENT; LEUKEMIA; MESENCHYMAL STEM CELL; MOLECULAR MECHANICS; MOTHER FETUS RELATIONSHIP; NATURAL KILLER CELL; NONHUMAN; PRIORITY JOURNAL; RECURRENT DISEASE; REGULATORY T LYMPHOCYTE; REVIEW; SOLUBILITY; T LYMPHOCYTE ACTIVATION; T LYMPHOCYTE SUBPOPULATION;

EID: 33745231146     PISSN: 00144827     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.yexcr.2006.03.019     Document Type: Review

References (103)

1. Dicker A., Le Blanc K., Astrom G., van Harmelen V., Gotherstrom C., Blomqvist L., Arner P., and Ryden M. Functional studies of mesenchymal stem cells derived from adult human adipose tissue. Exp. Cell Res. 308 (2005) 283-290
2. In 't Anker P.S., Scherjon S.A., Kleijburg-van der Keur C., de Groot-Swings G.M., Claas F.H., Fibbe W.E., and Kanhai H.H. Isolation of mesenchymal stem cells of fetal or maternal origin from human placenta. Stem Cells 22 (2004) 1338-1345
3. Shih D.T., Lee D.C., Chen S.C., Tsai R.Y., Huang C.T., Tsai C.C., Shen E.Y., and Chiu W.T. Isolation and characterization of neurogenic mesenchymal stem cells in human scalp tissue. Stem Cells 7 (2005) 1012-1020
4. Campagnoli C., Roberts I.A., Kumar S., Bennett P.R., Bellantuono I., and Fisk N.M. Identification of mesenchymal stem/progenitor cells in human first-trimester fetal blood, liver, and bone marrow. Blood 98 (2001) 2396-2402
5. Gotherstrom C., Ringden O., Westgren M., Tammik C., and Le Blanc K. Immunomodulatory effects of human foetal liver-derived mesenchymal stem cells. Bone Marrow Transplant. 32 (2003) 265-272
6. Pittenger M.F., Mosca J.D., and McIntosh K.R. Human mesenchymal stem cells: progenitor cells for cartilage, bone, fat and stroma. Curr. Top. Microbiol. Immunol. 251 (2000) 3-11
7. Le Blanc K., Tammik C., Rosendahl K., Zetterberg E., and Ringden O. HLA expression and immunologic properties of differentiated and undifferentiated mesenchymal stem cells. Exp. Hematol. 31 (2003) 890-896
8. Rangappa S., Entwistle J.W., Wechsler A.S., and Kresh J.Y. Cardiomyocyte-mediated contact programs human mesenchymal stem cells to express cardiogenic phenotype. J. Thorac. Cardiovasc. Surg. 126 (2003) 124-132
9. Xu W., Zhang X., Qian H., Zhu W., Sun X., Hu J., Zhou H., and Chen Y. Mesenchymal stem cells from adult human bone marrow differentiate into a cardiomyocyte phenotype in vitro. Exp. Biol. Med. (Maywood) 229 (2004) 623-631
10. Gang E.J., Jeong J.A., Hong S.H., Hwang S.H., Kim S.W., Yang I.H., Ahn C., Han H., and Kim H. Skeletal myogenic differentiation of mesenchymal stem cells isolated from human umbilical cord blood. Stem Cells 22 (2004) 617-624
11. Dezawa M., Ishikawa H., Itokazu Y., Yoshihara T., Hoshino M., Takeda S., Ide C., and Nabeshima Y. Bone marrow stromal cells generate muscle cells and repair muscle degeneration. Science 309 (2005) 314-317
12. Hong S.H., Gang E.J., Jeong J.A., Ahn C., Hwang S.H., Yang I.H., Park H.K., Han H., and Kim H. In vitro differentiation of human umbilical cord blood-derived mesenchymal stem cells into hepatocyte-like cells. Biochem. Biophys. Res. Commun. 330 (2005) 1153-1161
13. Oswald J., Boxberger S., Jorgensen B., Feldmann S., Ehninger G., Bornhauser M., and Werner C. Mesenchymal stem cells can be differentiated into endothelial cells in vitro. Stem Cells 22 (2004) 377-384
14. Sanchez-Ramos J., Song S., Cardozo-Pelaez F., Hazzi C., Stedeford T., Willing A., Freeman T.B., Saporta S., Janssen W., Patel N., Cooper D.R., and Sanberg P.R. Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp. Neurol. 164 (2000) 247-256
15. Woodbury D., Schwarz E.J., Prockop D.J., and Black I.B. Adult rat and human bone marrow stromal cells differentiate into neurons. J. Neurosci. Res. 61 (2000) 364-370
16. Jeong J.A., Gang E.J., Hong S.H., Hwang S.H., Kim S.W., Yang I.H., Ahn C., Han H., and Kim H. Rapid neural differentiation of human cord blood-derived mesenchymal stem cells. NeuroReport 15 (2004) 1731-1734
17. Horwitz E.M., Le Blanc K., Dominici M., Mueller I., Slaper-Cortenbach I., Marini F.C., Deans R.J., Krause D.S., and Keating A. Clarification of the nomenclature for MSC: the International Society for Cellular Therapy position statement. Cytotherapy 7 (2005) 393-395
18. Bartholomew A., Sturgeon C., Siatskas M., Ferrer K., McIntosh K., Patil S., Hardy W., Devine S., Ucker D., Deans R., Moseley A., and Hoffman R. Mesenchymal stem cells suppress lymphocyte proliferation in vitro and prolong skin graft survival in vivo. Exp. Hematol. 30 (2002) 42-48
19. Potian J.A., Aviv H., Ponzio N.M., Harrison J.S., and Rameshwar P. Veto-like activity of mesenchymal stem cells: functional discrimination between cellular responses to alloantigens and recall antigens. J. Immunol. 171 (2003) 3426-3434
20. Maitra B., Szekely E., Gjini K., Laughlin M.J., Dennis J., Haynesworth S.E., and Koc O.N. Human mesenchymal stem cells support unrelated donor hematopoietic stem cells and suppress T-cell activation. Bone Marrow Transplant. 33 (2004) 597-604
21. Tse W.T., Pendleton J.D., Beyer W.M., Egalka M.C., and Guinan E.C. Suppression of allogeneic T-cell proliferation by human marrow stromal cells: implications in transplantation. Transplantation 75 (2003) 389-397
22. + T-cell subsets expressing a regulatory/suppressive phenotype. Haematologica 90 (2005) 516-525
23. Klyushnenkova E., Mosca J.D., Zernetkina V., Majumdar M.K., Beggs K.J., Simonetti D.W., Deans R.J., and McIntosh K.R. T cell responses to allogeneic human mesenchymal stem cells: immunogenicity, tolerance, and suppression. J. Biomed Sci. 12 (2005) 47-57
24. Krampera M., Glennie S., Dyson J., Scott D., Laylor R., Simpson E., and Dazzi F. Bone marrow mesenchymal stem cells inhibit the response of naive and memory antigen-specific T cells to their cognate peptide. Blood 101 (2003) 3722-3729
25. Le Blanc K., Tammik L., Sundberg B., Haynesworth S.E., and Ringden O. Mesenchymal stem cells inhibit and stimulate mixed lymphocyte cultures and mitogenic responses independently of the major histocompatibility complex. Scand. J. Immunol. 57 (2003) 11-20
26. Di Nicola M., Carlo-Stella C., Magni M., Milanesi M., Longoni P.D., Matteucci P., Grisanti S., and Gianni A.M. Human bone marrow stromal cells suppress T-lymphocyte proliferation induced by cellular or nonspecific mitogenic stimuli. Blood 99 (2002) 3838-3843
27. Le Blanc K., Rasmusson I., Gotherstrom C., Seidel C., Sundberg B., Sundin M., Rosendahl K., Tammik C., and Ringden O. Mesenchymal stem cells inhibit the expression of CD25 (interleukin-2 receptor) and CD38 on phytohaemagglutinin-activated lymphocytes. Scand. J. Immunol. 60 (2004) 307-315
28. Djouad F., Plence P., Bony C., Tropel P., Apparailly F., Sany J., Noel D., and Jorgensen C. Immunosuppressive effect of mesenchymal stem cells favors tumor growth in allogeneic animals. Blood 102 (2003) 3837-3844
29. Aggarwal S., and Pittenger M.F. Human mesenchymal stem cells modulate allogeneic immune cell responses. Blood 105 (2005) 1815-1822
30. Glennie S., Soeiro I., Dyson P.J., Lam E.W., and Dazzi F. Bone marrow mesenchymal stem cells induce division arrest anergy of activated T cells. Blood 105 (2005) 2821-2827
31. Augello A., Tasso R., Negrini S.M., Amateis A., Indiveri F., Cancedda R., and Pennesi G. Bone marrow mesenchymal progenitor cells inhibit lymphocyte proliferation by activation of the programmed death 1 pathway. Eur. J. Immunol. 35 (2005) 1482-1490
32. Groh M.E., Maitra B., Szekely E., and Koc O.N. Human mesenchymal stem cells require monocyte-mediated activation to suppress alloreactive T cells. Exp. Hematol. 33 (2005) 928-934
33. Liu J., Lu X.F., Wan L., Li Y.P., Li S.F., Zeng L.Y., Zeng Y.Z., Cheng L.H., Lu Y.R., and Cheng J.Q. Suppression of human peripheral blood lymphocyte proliferation by immortalized mesenchymal stem cells derived from bone marrow of Banna Minipig inbred-line. Transplant. Proc. 36 (2004) 3272-3275
34. Zhang W., Ge W., Li C., You S., Liao L., Han Q., Deng W., and Zhao R.C. Effects of mesenchymal stem cells on differentiation, maturation, and function of human monocyte-derived dendritic cells. Stem Cells Dev. 13 (2004) 263-271
35. Beyth S., Borovsky Z., Mevorach D., Liebergall M., Gazit Z., Aslan H., Galun E., and Rachmilewitz J. Human mesenchymal stem cells alter antigen-presenting cell maturation and induce T-cell unresponsiveness. Blood 105 (2005) 2214-2219
36. Jiang X.X., Zhang Y., Liu B., Zhang S.X., Wu Y., Yu X.D., and Mao N. Human mesenchymal stem cells inhibit differentiation and function of monocyte-derived dendritic cells. Blood 105 (2005) 4120-4126
37. DeSilva D.R., Urdahl K.B., and Jenkins M.K. Clonal anergy is induced in vitro by T cell receptor occupancy in the absence of proliferation. J. Immunol. 147 (1991) 3261-3267
38. Majumdar M.K., Keane-Moore M., Buyaner D., Hardy W.B., Moorman M.A., McIntosh K.R., and Mosca J.D. Characterization and functionality of cell surface molecules on human mesenchymal stem cells. J. Biomed. Sci. 10 (2003) 228-241
39. Sakaguchi S., Sakaguchi N., Asano M., Itoh M., and Toda M. Immunologic self-tolerance maintained by activated T cells expressing IL-2 receptor alpha-chains (CD25). Breakdown of a single mechanism of self-tolerance causes various autoimmune diseases. J. Immunol. 155 (1995) 1151-1164
40. Asano M., Toda M., Sakaguchi N., and Sakaguchi S. Autoimmune disease as a consequence of developmental abnormality of a T cell subpopulation. J. Exp. Med. 184 (1996) 387-396
41. Jonuleit H., Schmitt E., Stassen M., Tuettenberg A., Knop J., and Enk A.H. Identification and functional characterization of human CD4(+)CD25(+) T cells with regulatory properties isolated from peripheral blood. J. Exp. Med. 193 (2001) 1285-1294
42. Kiessling R., Petranyi G., Karre K., Jondal M., Tracey D., and Wigzell H. Killer cells: a functional comparison between natural, immune T-cell and antibody-dependent in vitro systems. J. Exp. Med. 143 (1976) 772-780
43. Karre K. Immunology. A perfect mismatch. Science 295 (2002) 2029-2031
44. Malmberg K.J., Schaffer M., Ringden O., Remberger M., and Ljunggren H.G. KIR-ligand mismatch in allogeneic hematopoietic stem cell transplantation. Mol. Immunol. 42 (2005) 531-534
45. Rasmusson I., Ringden O., Sundberg B., and Le Blanc K. Mesenchymal stem cells inhibit the formation of cytotoxic T lymphocytes, but not activated cytotoxic T lymphocytes or natural killer cells. Transplantation 76 (2003) 1208-1213
46. Angoulvant D., Clerc A., Benchalal S., Galambrun C., Farre A., Bertrand Y., and Eljaafari A. Human mesenchymal stem cells suppress induction of cytotoxic response to alloantigens. Biorheology 41 (2004) 469-476
47. Kang H.S., Habib M., Chan J., Abavana C., Potian J.A., Ponzio N.M., and Rameshwar P. A paradoxical role for IFN-gamma in the immune properties of mesenchymal stem cells during viral challenge. Exp. Hematol. 33 (2005) 796-803
48. Rammensee H.G., Fink P.J., and Bevan M.J. Functional clonal deletion of class I-specific cytotoxic T lymphocytes by veto cells that express antigen. J. Immunol. 133 (1984) 2390-2396
49. Rasmusson I., Ringden O., Sundberg B., and Le Blanc K. Mesenchymal stem cells inhibit lymphocyte proliferation by mitogens and alloantigens by different mechanisms. Exp. Cell Res. 305 (2005) 33-41
50. Gotherstrom C., West A., Liden J., Uzunel M., Lahesmaa R., and Le Blanc K. Difference in gene expression between human fetal liver and adult bone marrow mesenchymal stem cells. Haematologica 90 (2005) 1017-1026
51. Haynesworth S.E., Baber M.A., and Caplan A.I. Cytokine expression by human marrow-derived mesenchymal progenitor cells in vitro: effects of dexamethasone and IL-1 alpha. J. Cell. Physiol. 166 (1996) 585-592
52. Silva Jr. W.A., Covas D.T., Panepucci R.A., Proto-Siqueira R., Siufi J.L., Zanette D.L., Santos A.R., and Zago M.A. The profile of gene expression of human marrow mesenchymal stem cells. Stem Cells 21 (2003) 661-669
53. Poznansky M.C., Olszak I.T., Foxall R., Evans R.H., Luster A.D., and Scadden D.T. Active movement of T cells away from a chemokine. Nat. Med. 6 (2000) 543-548
54. Tashiro K., Tada H., Heilker R., Shirozu M., Nakano T., and Honjo T. Signal sequence trap: a cloning strategy for secreted proteins and type I membrane proteins. Science 261 (1993) 600-603
55. Theill L.E., Boyle W.J., and Penninger J.M. RANK-L and RANK: T cells, bone loss, and mammalian evolution. Annu. Rev. Immunol. 20 (2002) 795-823
56. Lacey D.L., Timms E., Tan H.L., Kelley M.J., Dunstan C.R., Burgess T., Elliott R., Colombero A., Elliott G., Scully S., Hsu H., Sullivan J., Hawkins N., Davy E., Capparelli C., Eli A., Qian Y.X., Kaufman S., Sarosi I., Shalhoub V., Senaldi G., Guo J., Delaney J., and Boyle W.J. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 93 (1998) 165-176
57. Mbalaviele G., Abu-Amer Y., Meng A., Jaiswal R., Beck S., Pittenger M.F., Thiede M.A., and Marshak D.R. Activation of peroxisome proliferator-activated receptor-gamma pathway inhibits osteoclast differentiation. J. Biol. Chem. 275 (2000) 14388-14393
58. Roper R.L., Ludlow J.W., and Phipps R.P. Prostaglandin E2 inhibits B lymphocyte activation by a cAMP-dependent mechanism: PGE-inducible regulatory proteins. Cell. Immunol. 154 (1994) 296-308
59. + T regulatory type 1 response by cyclooxygenase-2-overexpressing glioma. J. Immunol. 173 (2004) 4352-4359
60. Arikawa T., Omura K., and Morita I. Regulation of bone morphogenetic protein-2 expression by endogenous prostaglandin E2 in human mesenchymal stem cells. J. Cell. Physiol. 200 (2004) 400-406
61. Munn D.H., Shafizadeh E., Attwood J.T., Bondarev I., Pashine A., and Mellor A.L. Inhibition of T cell proliferation by macrophage tryptophan catabolism. J. Exp. Med. 189 (1999) 1363-1372
62. Hwu P., Du M.X., Lapointe R., Do M., Taylor M.W., and Young H.A. Indoleamine 2,3-dioxygenase production by human dendritic cells results in the inhibition of T cell proliferation. J. Immunol. 164 (2000) 3596-3599
63. Frumento G., Rotondo R., Tonetti M., Damonte G., Benatti U., and Ferrara G.B. Tryptophan-derived catabolites are responsible for inhibition of T and natural killer cell proliferation induced by indoleamine 2,3-dioxygenase. J. Exp. Med. 196 (2002) 459-468
64. Munn D.H., Sharma M.D., Hou D., Baban B., Lee J.R., Antonia S.J., Messina J.L., Chandler P., Koni P.A., and Mellor A.L. Expression of indoleamine 2,3-dioxygenase by plasmacytoid dendritic cells in tumor-draining lymph nodes. J. Clin. Invest. 114 (2004) 280-290
65. Meisel R., Zibert A., Laryea M., Gobel U., Daubener W., and Dilloo D. Human bone marrow stromal cells inhibit allogeneic T-cell responses by indoleamine 2,3-dioxygenase-mediated tryptophan degradation. Blood 103 (2004) 4619-4621
66. Frumento G., Rotondo R., Tonetti M., and Ferrara G.B. T cell proliferation is blocked by indoleamine 2,3-dioxygenase. Transplant. Proc. 33 (2001) 428-430
67. Fallarino F., Grohmann U., Vacca C., Orabona C., Spreca A., Fioretti M.C., and Puccetti P. T cell apoptosis by kynurenines. Adv. Exp. Med. Biol. 527 (2003) 183-190
68. Zappia E., Casazza S., Pedemonte E., Benvenuto F., Bonanni I., Gerdoni E., Giunti D., Ceravolo A., Cazzanti F., Frassoni F., Mancardi G., and Uccelli A. Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T cell anergy. Blood 106 (2005) 1755-1761
69. Plumas J., Chaperot L., Richard M.J., Molens J.P., Bensa J.C., and Favrot M.C. Mesenchymal stem cells induce apoptosis of activated T cells. Leukemia 19 (2005) 1597-1604
70. Goodman E.R., Fiedor P.S., Fein S., Athan E., and Hardy M.A. Fludarabine phosphate: a DNA synthesis inhibitor with potent immunosuppressive activity and minimal clinical toxicity. Am. Surg. 62 (1996) 435-442
71. Ossevoort M.A., Lorre K., Boon L., van den Hout Y., de Boer M., De Waele P., Jonker M., and VandeVoorde A. Prolonged skin graft survival by administration of anti-CD80 monoclonal antibody with cyclosporin A. J. Immunother. 22 (1999) 381-389
72. Grinnemo K.H., Mansson A., Dellgren G., Klingberg D., Wardell E., Drvota V., Tammik C., Holgersson J., Ringden O., Sylven C., and Le Blanc K. Xenoreactivity and engraftment of human mesenchymal stem cells transplanted into infarcted rat myocardium. J. Thorac. Cardiovasc. Surg. 127 (2004) 1293-1300
73. van B.D., van P.L., and de V.M. Antihost reactivity and tolerance of the graft in relation to secondary disease in radiation chimeras. Ann. N. Y. Acad. Sci. 99 (1962) 550-563
74. Storb R., and Thomas E.D. Graft-versus-host disease in dog and man: the Seattle experience. Immunol. Rev. 88 (1985) 215-238
75. Hill G.R., and Ferrara J.L. The primacy of the gastrointestinal tract as a target organ of acute graft-versus-host disease: rationale for the use of cytokine shields in allogeneic bone marrow transplantation. Blood 95 (2000) 2754-2759
76. Xun C.Q., Thompson J.S., Jennings C.D., Brown S.A., and Widmer M.B. Effect of total body irradiation, busulfan-cyclophosphamide, or cyclophosphamide conditioning on inflammatory cytokine release and development of acute and chronic graft-versus-host disease in H-2-incompatible transplanted SCID mice. Blood 83 (1994) 2360-2367
77. Paris F., Fuks Z., Kang A., Capodieci P., Juan G., Ehleiter D., Haimovitz-Friedman A., Cordon-Cardo C., and Kolesnick R. Endothelial apoptosis as the primary lesion initiating intestinal radiation damage in mice. Science 293 (2001) 293-297
78. Weiden P.L., Flournoy N., Thomas E.D., Prentice R., Fefer A., Buckner C.D., and Storb R. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. N. Engl. J. Med. 300 (1979) 1068-1073
79. Horowitz M.M., Gale R.P., Sondel P.M., Goldman J.M., Kersey J., Kolb H.J., Rimm A.A., Ringden O., Rozman C., Speck B., et al. Graft-versus-leukemia reactions after bone marrow transplantation. Blood 75 (1990) 555-562
80. Ringden O., Labopin M., Gorin N.C., Schmitz N., Schaefer U.W., Prentice H.G., Bergmann L., Jouet J.P., Mandelli F., Blaise D., Fouillard L., and Frassoni F. Is there a graft-versus-leukaemia effect in the absence of graft-versus-host disease in patients undergoing bone marrow transplantation for acute leukaemia?. Br. J. Haematol. 111 (2000) 1130-1137
81. Shlomchik W.D., Couzens M.S., Tang C.B., McNiff J., Robert M.E., Liu J., Shlomchik M.J., and Emerson S.G. Prevention of graft versus host disease by inactivation of host antigen-presenting cells. Science 285 (1999) 412-415
82. Teshima T., Ordemann R., Reddy P., Gagin S., Liu C., Cooke K.R., and Ferrara J.L. Acute graft-versus-host disease does not require alloantigen expression on host epithelium. Nat. Med. 8 (2002) 575-581
83. Chung N.G., Jeong D.C., Park S.J., Choi B.O., Cho B., Kim H.K., Chun C.S., Won J.H., and Han C.W. Cotransplantation of marrow stromal cells may prevent lethal graft-versus-host disease in major histocompatibility complex mismatched murine hematopoietic stem cell transplantation. Int. J. Hematol. 80 (2004) 370-376
84. Lazarus H.M., Haynesworth S.E., Gerson S.L., Rosenthal N.S., and Caplan A.I. Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant. 16 (1995) 557-564
85. Lazarus H.M., Koc O.N., Devine S.M., Curtin P., Maziarz R.T., Holland H.K., Shpall E.J., McCarthy P., Atkinson K., Cooper B.W., Gerson S.L., Laughlin M.J., Loberiza Jr. F.R., Moseley A.B., and Bacigalupo A. Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol. Blood Marrow Transplant. 11 (2005) 389-398
86. Lee S.T., Jang J.H., Cheong J.W., Kim J.S., Maemg H.Y., Hahn J.S., Ko Y.W., and Min Y.H. Treatment of high-risk acute myelogenous leukaemia by myeloablative chemoradiotherapy followed by co-infusion of T cell-depleted haematopoietic stem cells and culture-expanded marrow mesenchymal stem cells from a related donor with one fully mismatched human leucocyte antigen haplotype. Br. J. Haematol. 118 (2002) 1128-1131
87. Le Blanc K., Rasmusson I., Sundberg B., Gotherstrom C., Hassan M., Uzunel M., and Ringden O. Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 363 (2004) 1439-1441
88. Suniara R.K., Jenkinson E.J., and Owen J.J. An essential role for thymic mesenchyme in early T cell development. J. Exp. Med. 191 (2000) 1051-1056
89. Bacigalupo A., Valle M., Podesta M., Pitto A., Zocchi E., De Flora A., Pozzi S., Luchetti S., Frassoni F., Van Lint M.T., and Piaggio G. T-cell suppression mediated by mesenchymal stem cells is deficient in patients with severe aplastic anemia. Exp. Hematol. 33 (2005) 819-827
90. Barry F.P., Murphy J.M., English K., and Mahon B.P. Immunogenicity of adult mesenchymal stem cells: lessons from the fetal allograft. Stem Cells Dev. 14 (2005) 252-265
91. Bonney E.A., and Matzinger P. The maternal immune system's interaction with circulating fetal cells. J. Immunol. 158 (1997) 40-47
92. Moreau P., Adrian-Cabestre F., Menier C., Guiard V., Gourand L., Dausset J., Carosella E.D., and Paul P. IL-10 selectively induces HLA-G expression in human trophoblasts and monocytes. Int. Immunol. 11 (1999) 803-811
93. Raghupathy R., Makhseed M., Azizieh F., Hassan N., Al-Azemi M., and Al-Shamali E. Maternal Th1- and Th2-type reactivity to placental antigens in normal human pregnancy and unexplained recurrent spontaneous abortions. Cell. Immunol. 196 (1999) 122-130
94. Power L.L., Popplewell E.J., Holloway J.A., Diaper N.D., Warner J.O., and Jones C.A. Immunoregulatory molecules during pregnancy and at birth. J. Reprod. Immunol. 56 (2002) 19-28
95. Parrott J.A., and Skinner M.K. Thecal cell-granulosa cell interactions involve a positive feedback loop among keratinocyte growth factor, hepatocyte growth factor, and Kit ligand during ovarian follicular development. Endocrinology 139 (1998) 2240-2245
96. Arosh J.A., Banu S.K., Chapdelaine P., Madore E., Sirois J., and Fortier M.A. Prostaglandin biosynthesis, transport, and signaling in corpus luteum: a basis for autoregulation of luteal function. Endocrinology 145 (2004) 2551-2560
97. Munn D.H., Zhou M., Attwood J.T., Bondarev I., Conway S.J., Marshall B., Brown C., and Mellor A.L. Prevention of allogeneic fetal rejection by tryptophan catabolism. Science 281 (1998) 1191-1193
98. Schrocksnadel K., Widner B., Bergant A., Neurauter G., Schrocksnadel H., and Fuchs D. Tryptophan degradation during and after gestation. Adv. Exp. Med. Biol. 527 (2003) 77-83
99. Schrocksnadel K., Widner B., Bergant A., Neurauter G., Schennach H., Schrocksnadel H., and Fuchs D. Longitudinal study of tryptophan degradation during and after pregnancy. Life Sci. 72 (2003) 785-793
100. In 't Anker P.S., Scherjon S.A., Kleijburg-van der Keur C., Noort W.A., Claas F.H., Willemze R., Fibbe W.E., and Kanhai H.H. Amniotic fluid as a novel source of mesenchymal stem cells for therapeutic transplantation. Blood 102 (2003) 1548-1549
101. Mareschi K., Biasin E., Piacibello W., Aglietta M., Madon E., and Fagioli F. Isolation of human mesenchymal stem cells: bone marrow versus umbilical cord blood. Haematologica 86 (2001) 1099-1100
102. in 't Anker P.S., Noort W.A., Scherjon S.A., Kleijburg-van der Keur C., Kruisselbrink A.B., van Bezooijen R.L., Beekhuizen W., Willemze R., Kanhai H.H., and Fibbe W.E. Mesenchymal stem cells in human second-trimester bone marrow, liver, lung, and spleen exhibit a similar immunophenotype but a heterogeneous multilineage differentiation potential. Haematologica 88 (2003) 845-852
103. Gotherstrom C., Ringden O., Tammik C., Zetterberg E., Westgren M., and Le Blanc K. Immunologic properties of human fetal mesenchymal stem cells. Am. J. Obstet. Gynecol. 190 (2004) 239-245